Journal article
Late onset imatinib-induced Stevens-Johnson syndrome
Journal of oncology pharmacy practice, Vol.20(6), pp.476-478
12/2014
DOI: 10.1177/1078155213518226
PMID: 24399835
Abstract
Imatinib, a BCR-ABL tyrosine kinase inhibitor, is known to cause mild to moderate cutaneous reactions in up to approximately 20% of patients. It rarely causes severe reactions, such as Stevens-Johnson syndrome, which can be life threatening. Typically, these rashes occur within two months of initiating therapy. We report a case of Stevens-Johnson syndrome induced by imatinib after several years of therapy, but later successfully was treated with nilotinib therapy.
Details
- Title: Subtitle
- Late onset imatinib-induced Stevens-Johnson syndrome
- Creators
- Evan Bois - Rite Aid, Waterville, ME, USALisa M Holle - Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA lisa.holle@uconn.eduUmar Farooq - Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA
- Resource Type
- Journal article
- Publication Details
- Journal of oncology pharmacy practice, Vol.20(6), pp.476-478
- DOI
- 10.1177/1078155213518226
- PMID
- 24399835
- ISSN
- 1078-1552
- eISSN
- 1477-092X
- Language
- English
- Date published
- 12/2014
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094351202771
Metrics
22 Record Views